283 related articles for article (PubMed ID: 36558033)
1. Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights.
Suriya U; Mahalapbutr P; Wimonsong W; Yotphan S; Choowongkomon K; Rungrotmongkol T
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558033
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
[TBL] [Abstract][Full Text] [Related]
3. Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR.
Todsaporn D; Mahalapbutr P; Poo-Arporn RP; Choowongkomon K; Rungrotmongkol T
Comput Biol Med; 2022 Aug; 147():105787. PubMed ID: 35803080
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study.
Todsaporn D; Zubenko A; Kartsev V; Aiebchun T; Mahalapbutr P; Petrou A; Geronikaki A; Divaeva L; Chekrisheva V; Yildiz I; Choowongkomon K; Rungrotmongkol T
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049777
[TBL] [Abstract][Full Text] [Related]
5. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
[TBL] [Abstract][Full Text] [Related]
6. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
[TBL] [Abstract][Full Text] [Related]
7. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.
Zhu Y; Ye X; Shen H; Li J; Cai Z; Min W; Hou Y; Dong H; Wu Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2023 Nov; 66(21):14633-14652. PubMed ID: 37885208
[TBL] [Abstract][Full Text] [Related]
9. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.
Wang C; Wang X; Huang Z; Wang T; Nie Y; Yang S; Xiang R; Fan Y
Eur J Med Chem; 2022 Jul; 237():114381. PubMed ID: 35447433
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel nitroflavone-based scaffold for designing mutant-selective EGFR tyrosine kinase inhibitors targeting T790M and C797S resistance in advanced NSCLC.
Cristina M; Emiliano L; Leonardo S; Giulia S; Roberta G; Adolfo A; Marta SS; Paola S; Samuele R; Pierluigi S; Massimo M; Giovanna M
Bioorg Chem; 2022 Dec; 129():106219. PubMed ID: 36308853
[TBL] [Abstract][Full Text] [Related]
12. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
[TBL] [Abstract][Full Text] [Related]
13.
Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors.
Zhang M; Yang Y; Wang Y; Wang J; Wu H; Zhu Y
Chem Pharm Bull (Tokyo); 2023 Feb; 71(2):140-147. PubMed ID: 36517026
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
[TBL] [Abstract][Full Text] [Related]
16. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.
Singh A; Mishra A
J Biomol Struct Dyn; 2023 Jul; 41(10):4534-4548. PubMed ID: 35510318
[TBL] [Abstract][Full Text] [Related]
17. Modification of osimertinib to discover new potent EGFR
Xi XX; Zhao HY; Mao YZ; Xin M; Zhang SQ
Eur J Med Chem; 2023 Dec; 261():115865. PubMed ID: 37839342
[TBL] [Abstract][Full Text] [Related]
18. Novel bioactive 2-phenyl-4-aminopyrimidine derivatives as EGFR
Xu S; Zhou Z; He J; Guo J; Huang X; An Y; Pan Q; Xu S; Zhu W
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300460. PubMed ID: 38009481
[TBL] [Abstract][Full Text] [Related]
19. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
20. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.
Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H
J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]